Ferdinandos Skoulidis

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

F Skoulidis, F. Skoulidis, Ferdinandos Skoulidis, Skoulidis, Ferdinandos

427

Publications

16.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Amgen (United States)NYU Langone Health

About

Ferdinandos Skoulidis is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, radiation oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	31	4.7K
2	Health Sciences	10	11	1.5K
3	Engineering	1	1	26
4	Natural Sciences	1	1	320
5	Biomolecular Engineering	1	1	320

Ferdinandos Skoulidis

Publications

14.7K

Citations

H-Index

Page 1

	Year	Citations
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, New England Journal of Medicine	2021	1.6K
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Cancer Discovery	2018	1.5K
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study Daniel R. Gomez, Chad Tang, Jianjun Zhang, Journal of Clinical Oncology	2019	1.2K
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study Daniel R. Gomez, George R. Blumenschein, J. Jack Lee, The Lancet Oncology First-line Systemic TherapyMedicineCancer ManagementBronchial NeoplasmCombined Modality Treatment	2016	1.1K
Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Cancer Discovery	2015	883
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Cancer Research	2016	605
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Tina Cascone, William N. William, Annikka Weissferdt, Nature Medicine Neostar TrialMedicineImmune Checkpoint InhibitorCancer TreatmentPhase 2	2021	582
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Milena Perez Mak, Pan Tong, Lixia Diao, Clinical Cancer Research	2015	560
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials Willemijn S.M.E. Theelen, Dawei Chen, Vivek Verma, The Lancet Respiratory Medicine MedicineRandomised TrialsImmune Checkpoint InhibitorBronchial NeoplasmCancer Treatment	2020	540
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières, The Lancet Non-small-cell Lung CancerMedicinePathologyCancer TreatmentCancer Genetics	2023	507

Page 1